Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. [electronic resource]
Producer: 20110425Description: 177-83 p. digitalISSN:- 1473-5687
- Adult
- Antiviral Agents -- therapeutic use
- Biomarkers -- blood
- Drug Monitoring -- methods
- Drug Therapy, Combination
- Female
- Hepatitis C, Chronic -- drug therapy
- Humans
- Interferon alpha-2
- Interferon-alpha -- therapeutic use
- Male
- Middle Aged
- Polyethylene Glycols -- therapeutic use
- Prospective Studies
- Proteomics
- Recombinant Proteins
- Ribavirin -- therapeutic use
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.